- Home
- EDSA vs NXTC Comparison
EDSA vs NXTC Comparison
Compare EDSA & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- NXTC
- Stock Information
- Founded
- EDSA 2015
- NXTC 2015
- Country
- EDSA Canada
- NXTC United States
- Employees
- EDSA N/A
- NXTC N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- NXTC Health Care
- Exchange
- EDSA Nasdaq
- NXTC Nasdaq
- Market Cap
- EDSA 15.9M
- NXTC 13.9M
- IPO Year
- EDSA N/A
- NXTC 2019
- Fundamental
- Price
- EDSA $2.11
- NXTC $4.80
- Analyst Decision
- EDSA Strong Buy
- NXTC Strong Buy
- Analyst Count
- EDSA 2
- NXTC 2
- Target Price
- EDSA $13.00
- NXTC $25.50
- AVG Volume (30 Days)
- EDSA 38.0K
- NXTC 325.3K
- Earning Date
- EDSA 08-08-2025
- NXTC 08-07-2025
- Dividend Yield
- EDSA N/A
- NXTC N/A
- EPS Growth
- EDSA N/A
- NXTC N/A
- EPS
- EDSA N/A
- NXTC N/A
- Revenue
- EDSA N/A
- NXTC N/A
- Revenue This Year
- EDSA N/A
- NXTC N/A
- Revenue Next Year
- EDSA N/A
- NXTC N/A
- P/E Ratio
- EDSA N/A
- NXTC N/A
- Revenue Growth
- EDSA N/A
- NXTC N/A
- 52 Week Low
- EDSA $1.55
- NXTC $2.69
- 52 Week High
- EDSA $5.18
- NXTC $20.16
- Technical
- Relative Strength Index (RSI)
- EDSA 42.63
- NXTC 42.50
- Support Level
- EDSA $2.02
- NXTC $4.75
- Resistance Level
- EDSA $2.35
- NXTC $5.42
- Average True Range (ATR)
- EDSA 0.14
- NXTC 0.43
- MACD
- EDSA -0.03
- NXTC -0.01
- Stochastic Oscillator
- EDSA 18.00
- NXTC 2.99
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.